Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | SVP, CFO | August 06, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date August 06, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 638 |
Reported balance
After 2026-08-06 transaction · row 1
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 638 · Balance 638 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Exercise / conversion · Disposed 638 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2: On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 11, 2026 01:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 638 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-343077 · ownership.xml · derivative · entry 2 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant. F2 · derivative.expiration_date: On August 6, 2025, the reporting person was granted 11,500 (638 post-split) RSUs, vesting on the first anniversary of the date of grant. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 01:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-343077 · ownership.xml · nonDerivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:35 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-105938 · ownership.xml · derivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the date of grant. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:38 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 3 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-097272 · ownership.xml · derivative · entry 2 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8 Underlying: Common Stock · 11 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On July 17, 2024, the reporting person was granted 8,550 (11 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. F2 · derivative.expiration_date: On July 17, 2024, the reporting person was granted 8,550 (11 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:38 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 3 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-097272 · ownership.xml · nonDerivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:32 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032183 · ownership.xml · derivative · entry 4 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 4,750 (3 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 4, 2023. F3 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 4,750 (3 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 4, 2023. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:32 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-032183 · ownership.xml · nonDerivative · entry 2 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 21:32 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 2 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032183 · ownership.xml · derivative · entry 3 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 2 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 11,000 (7 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. F2 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 11,000 (7 post-splits) RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 21:32 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 2 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-032183 · ownership.xml · nonDerivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:30 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 158 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-094813 · ownership.xml · derivative · entry 2 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 158 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On August 9, 2022, the reporting person was granted 13,889 (315 post-split) RSUs, vesting in two approximately equal annual installments beginning on August 8, 2023. F2 · derivative.expiration_date: On August 9, 2022, the reporting person was granted 13,889 (315 post-split) RSUs, vesting in two approximately equal annual installments beginning on August 8, 2023. Read SEC document |
| August 08, 2024 Filed Aug 9, 2024 20:30 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 158 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-094813 · ownership.xml · nonDerivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 20:37 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 8,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-084955 · ownership.xml · derivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,550 Underlying: Common Stock · 8,550 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on July 17, 2025. F2 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on July 17, 2025. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:13 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025921 · ownership.xml · derivative · entry 4 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,583 Underlying: Common Stock · 1,584 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 4,750 RSUs, vesting in three approximately equal annual installments beginning on March 4, 2023. F3 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 4,750 RSUs, vesting in three approximately equal annual installments beginning on March 4, 2023. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:13 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025921 · ownership.xml · nonDerivative · entry 2 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,411 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 21:13 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 3,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025921 · ownership.xml · derivative · entry 3 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,333 Underlying: Common Stock · 3,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On March 3, 2023, the reporting person was granted 11,000 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. F2 · derivative.expiration_date: On March 3, 2023, the reporting person was granted 11,000 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 21:13 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 3,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-025921 · ownership.xml · nonDerivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 23:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-009005 · ownership.xml · derivative · entry 2 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On January 29, 2021, the reporting person was granted 2,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. F2 · derivative.expiration_date: On January 29, 2021, the reporting person was granted 2,375 RSUs, vesting in three approximately equal annual installments beginning on January 29, 2022. Read SEC document |
| January 29, 2024 Filed Jan 30, 2024 23:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 792 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-009005 · ownership.xml · nonDerivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 12:47 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 6,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045267 · doc4.xml · derivative · entry 2 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,944 Underlying: Common Stock · 6,945 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On August 9, 2022, the reporting person was granted 13,889 RSUs, vesting in two approximately equal installments beginning on August 8, 2023. F2 · derivative.expiration_date: On August 9, 2022, the reporting person was granted 13,889 RSUs, vesting in two approximately equal installments beginning on August 8, 2023. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 12:47 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 6,945 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045267 · doc4.xml · nonDerivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016783 · doc4.xml · derivative · entry 4 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,167 Underlying: Common Stock · 1,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F4 · derivative.exercise_date: On June 7, 2022, the reporting person was granted 4,750 RSUs, vesting in three approximately equal annual installments beginning on March 4, 2023. F4 · derivative.expiration_date: On June 7, 2022, the reporting person was granted 4,750 RSUs, vesting in three approximately equal annual installments beginning on March 4, 2023. Read SEC document |
| March 04, 2023 Filed Mar 7, 2023 21:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016783 · doc4.xml · nonDerivative · entry 1 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016783 · doc4.xml · derivative · entry 3 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on March 2, 2024. F3 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-23-016783 · doc4.xml · derivative · entry 2 Taylor Daphne · CIK 0001393549 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2033-03-02 F2 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on March 2, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.